capecitabine has been researched along with Adverse Drug Event in 67 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.49) | 18.2507 |
| 2000's | 7 (10.45) | 29.6817 |
| 2010's | 47 (70.15) | 24.3611 |
| 2020's | 12 (17.91) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Barton, DL; Chittiprolu, A; Cho, Y; Gong, Y; Harden, K; Harris, MR; Jiang, Y; Mason, M; Zhang, X | 1 |
| Bechar, H; Belahcen, MJ; Cherif Chefchaouni, A; Nouibi, C; Rahali, Y | 1 |
| Agatsuma, N; Imamaki, H; Nishikawa, Y; Oguro, F; Oura, M | 1 |
| Buunk, AM; Crommentuijn-van Rhenen, MH; de Boer-Veger, NJ; Deneer, VHM; Guchelaar, HJ; Houwink, EJF; Lunenburg, CATC; Mulder, H; Nijenhuis, M; Rongen, GA; Swen, JJ; van der Weide, J; van der Wouden, CH; van Schaik, RHN; Wilffert, B | 1 |
| Ariyoshi, K; Hamaguchi, R; Iwase, S; Miura, K; Miyata, G; Ohori, H; Oshio, H; Oyamada, S; Sato, T; Takahashi, K; Tsuchiya, T | 1 |
| Appel, JM; Dyhl-Polk, A; Kümler, T; Lund, CM; Nielsen, DL; Schou, M; Vaage-Nilsen, M; Vistisen, KK | 1 |
| Abramson, VG; Ayala-Peacock, DN; Chakravarthy, AB; Mayer, IA; Rexer, BN; Sherry, AD | 1 |
| Abramson, VG; Chang, JC; Cox, N; Dees, EC; Dolan, ME; Fleming, GF; Forero, A; Hahn, OM; Hall, JP; Hoffman, PC; Huang, RS; Huo, D; Ingle, JN; Liu, MC; Merkel, DE; Morrow, PK; Nanda, R; Nath, A; Nurhussein-Patterson, A; O'Donnell, PH; Olopade, OI; Peppercorn, JM; Ratain, MJ; Rosner, GL; Rugo, HS; Storniolo, AM; Trubetskoy, V; Van Poznak, C; Wolff, AC | 1 |
| Ariizumi, H; Fujita, KI; Hirasawa, Y; Hisamatsu, A; Ikusue, T; Ishida, H; Ishiguro, T; Kobayashi, K; Kubota, Y; Matsumoto, N; Ohkuma, R; Sekido, M; Shimada, K; Toshima, H; Tsunoda, T | 1 |
| Fang, F; Henry, NL; Hertz, DL; Kidwell, KM; Koo, K; Kwon, JW; Pasternak, AL; Sahai, V; Shakeel, F | 1 |
| Al-Tassan, NA; Cheadle, JP; Escott-Price, V; Gray, V; Houlston, RS; Kaplan, R; Kerr, D; Kerr, R; Madi, A; Maughan, TS; Palles, C; Watts, K; West, H; Wills, C | 1 |
| Aliev, A; Beijnen, JH; Cats, A; de Boer, A; de Vries, N; Deenen, MJ; Henricks, LM; Jacobs, BAW; Mandigers, CMPW; Meulendijks, D; Rosing, H; Schellens, JHM; Soesan, M; van Werkhoven, E | 1 |
| Blanco, C; García, MI; García-Alfonso, P; García-González, X; Grávalos, C; Iglesias, I; Longo, F; López-Fernández, LA; Martínez, J; Martínez, V; Pachón, V; Pellicer, M; Robles, L; Rueda, D; Salvador, S; Sanjurjo, M | 1 |
| García-González, X; López-Fernández, LA | 1 |
| Cho, JH; Cho, JY; Lim, JY | 1 |
| Bennett, DD; Burkard, ME; Shah, RA | 1 |
| Amstutz, U; Hamzic, S; Largiadèr, CR | 1 |
| Park, JY | 1 |
| Chu, E; Lee, JJ | 1 |
| Brutcher, E; Christensen, D; Hennessey Smith, M; Koutlas, JB; Sellers, JB; Thompson, J; Timmons, T | 1 |
| Awan, S; Frankel, AE; Hosein, PJ; Khushman, M; Maharjan, AS; McMillin, GA; Nelson, C; Pai, S; Patel, GK; Singh, AP; Taylor, WR; Wang, B | 1 |
| Dadduzio, V; Farinati, F; Giovanis, P; Imondi, A; Lombardi, G; Lonardi, S; Maddalo, G; Pastorelli, D; Pelizzaro, F; Peserico, G; Rizzato, MD; Sammarco, A; Sartori, A; Soldà, C | 1 |
| Cantelli, M; Fabbrocini, G; Fattore, D; Panariello, L | 1 |
| Gelderblom, H; Guchelaar, HJ; Punt, CJ; van Huis-Tanja, LH | 1 |
| Abrams, RA; Bridgewater, J; Crosby, T; Cummins, S; Falk, S; Griffiths, G; Hurt, CN; Jephcott, C; Joseph, G; Maughan, T; McDonald, A; Mukherjee, S; Radhakrishna, G; Ray, R; Roy, R; Staffurth, J; Wasan, H | 1 |
| Asbun, HJ; Awad, ZT; George, TJ; Ho, MW; Hoppe, BS; Huh, S; Mendenhall, NP; Morris, CG; Nichols, RC; Zaiden, RA | 1 |
| Alvarez Suarez, S; Blanco Codeidido, M; García Alfonso, P; López Martín, P; Martin, M; Mondejar Solis, R; Muñoz Martin, A; Tapia Rico, G | 1 |
| Badzek, S; Bilic, E; Golem, H; Gorsic, I; Kekez, D; Librenjak, N; Miletic, V; Plestina, S; Prejac, J | 1 |
| Al-Batran, SE; Gencer, D; Hartmann, JT; Hochhaus, A; Hofheinz, RD; Kripp, M; Merx, K; Miranda, MB | 1 |
| Jiang, Z; Liang, Y; Liu, F; Song, X; Wang, W; Wu, P; Xing, L; Xu, D; Yu, X; Zang, Q; Zhang, J | 1 |
| Afzal, S; Boige, V; Braun, M; Church, D; Domingo, E; Enghusen, H; Etienne-Grimaldi, MC; Garcia-Foncillas, J; Garmo, H; Glimelius, B; Gonzalez-Neira, A; Green, E; Gusella, M; Jensen, SA; Johnstone, E; Jones, A; Julier, P; Kerr, D; Kleibl, Z; Lacas, B; Laurent-Puig, P; Lecomte, T; Love, S; Martin, M; Martinez-Balibrea, E; McLeod, H; Midgley, R; Milano, G; Morel, A; Nicholson, G; Palles, C; Pignon, JP; Ribelles, N; Rosmarin, D; Sargent, D; Schwab, M; Scudder, C; Seymour, M; Sharma, R; Thompson, L; Tomlinson, I; Wadelius, M; Wang, H; Zanger, UM | 1 |
| Boukovinas, I; Christophylakis, C; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Karampeazis, A; Matikas, A; Polyzos, A; Souglakos, J; Vamvakas, L | 1 |
| Brammer, M; Guardino, E; Guerin, A; Hurvitz, S; Lalla, D; Latremouille Viau, D; Wu, EQ; Zhou, ZY | 1 |
| Akgun, Z; Balik, E; Cipe, G; Gural, Z; Kaytan-Saglam, E; Kilickap, S; Okyar, A; Saglam, S; Yildiz, S; Yucel, S | 1 |
| Albanell, J; Bellmunt, J; Beltran, M; Bonfill, T; Carles, J; Gallardo, E; Galtes, S; Moya, I; Pons, F; Rodon, J; Suarez, C | 1 |
| Bang, YJ; Chen, JS; Choi, JH; Chung, HC; Chung, IJ; Ha, S; Ji, J; Kim, HH; Kim, HK; Kim, SW; Lee, JI; Lim, Y; Noh, SH; Park, SR; Shin, DB; Yang, HK; Yu, W | 1 |
| Aktas, B; Aydogdu, M; Feisel-Schwickardi, G; Höffkes, HG; Illmer, T; Janni, W; Loibl, S; Lübbe, K; Lück, HJ; Maass, N; Mehta, K; Nekljudova, V; Neunhöffer, T; Ober, A; Park-Simon, TW; Reinisch, M; Schumacher, C; Tomé, O; von Minckwitz, G; Wagner, H | 1 |
| Chambers, CR; Danilak, M; Ghosh, S; Ilich, AI; Kim, CA; Mulder, KE; Sawyer, MB; Spratlin, JL | 1 |
| Deenen, MJ; Gelderblom, H; Guchelaar, HJ; Henricks, LM; Lunenburg, CATC; Schellens, JHM; Swen, JJ | 1 |
| Beijnen, JH; Cats, A; Deenen, MJ; Huitema, ADR; Meulendijks, D; Schellens, JHM; van Hasselt, JGC; van Tinteren, H | 1 |
| Arnold, D; Engelen, A; Göhler, T; Hinke, A; Höffkes, HG; Quidde, J; Schirrmacher-Memmel, S; Schröder, JK; Stein, A; Tschechne, B; Valdix, AR; Wohlfarth, T | 1 |
| Hu, XH; Jia, J; Li, YH; Lin, DR; Lin, YC; Luo, HY; Ma, D; Peng, JW; Wang, FH; Wang, W; Wang, ZQ; Xu, RH; Yuan, X; Zhang, DS | 1 |
| Bounthavong, M; Chen, T; Nguyen, CP; Wong, SF | 1 |
| Boven, E; Guchelaar, HJ; Lam, SW | 1 |
| Brunetti, ND; Caldarola, P; De Gennaro, L; Resta, M; Rutigliano, D; Tarantini, L | 1 |
| Berretta, M; De Paoli, A; Lestuzzi, C | 1 |
| Dalal, RP; Gao, L; Garcia, AA; Gradishar, W; Joy, AA; Kauh, J; Khatcheressian, J; Layman, R; Miller, K; Rodriguez, G; Salkeni, MA; Sparano, J; Tang, S; Vahdat, LT; Ward, P; Yardley, DA | 1 |
| Hofer, S; Krähenbühl, S; Ludwig, C; Rätz Bravo, AE | 1 |
| Greil, R; Menzel, C; Mlineritsch, B; Moik, M; Namberger, K; Reitsamer, R; Ressler, S; Stoll, M | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY | 1 |
| Chung, EK; Hahn, OM; Karrison, T; Kasza, K; Manchen, E; Posadas, EM; Stadler, WM | 1 |
| Alberola Candel, V; Cerezuela Fuentes, P; Gasent Blesa, JM; Giner Marco, V; Giner-Bosch, V | 1 |
| Baird, R; Barbachano, Y; Biondo, A; Chau, I; Chhaya, V; Cunningham, D; Karpathakis, A; McLachlan, J; Rahman, S | 1 |
| Cennamo, V; Fuccio, L | 1 |
| Backshall, A; Clarke, SJ; Keun, HC; Sharma, R | 1 |
| Beijnen, JH; Burylo, AM; Cats, A; de Boer, A; Deenen, MJ; Doodeman, VD; Guchelaar, HJ; Punt, CJ; Schellens, JH; Smits, PH; Tol, J; Vincent, A | 1 |
| Ross, JS | 1 |
| Akagi, Y; Ando, K; Emi, Y; Kakeji, Y; Kitazono, M; Maehara, Y; Morita, M; Natsugoe, S; Ogata, Y; Oki, E; Saeki, H; Sakaguchi, Y; Samura, H; Shirouzu, K; Sirzen, F; Tokunaga, S | 1 |
| Bachelot, T; Campone, M; Cropet, C; Curé, H; Dalenc, F; Diéras, V; Domont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Jimenez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Pierga, JY; Romieu, G | 1 |
| Blough, D; Koepl, L; Mummy, D; Ramsey, S; Shankaran, V; Yim, YM; Yu, E | 1 |
| Alexopoulos, A; Ardavanis, A; Karamouzis, M; Orfanos, G; Rigatos, G; Scorilas, A; Tryfonopoulos, D | 1 |
| Alvarez, JV; Arcediano, A; Cassinello, J; Castro, IG; Colmenarejo, A; Filipovich, E; López, MJ; Marcos, F; Pujol, E; Segovia, F | 1 |
| Cohen, RB; Eckhardt, SG; Gore, L; Gustafson, D; Holden, SN; Mikule, C; Morrow, M; O'Bryant, CL; Palmer, PA; Persky, M; Pierson, AS; Zhang, S | 1 |
| Gel-Moreno, B; Hernández-Borlan, R; Ibeas-Rollan, R; Martínez-Ródenas, F; Monzó-Planella, M; Moreno-Solórzano, I; Moreno-Solórzano, J; Navarro-Vigo, M; Ortigosa-Rodríguez, S; Pou-Sanchis, E | 1 |
| Saif, MW; Tejani, MA | 1 |
| Davis, WM; Waters, IW | 1 |
8 review(s) available for capecitabine and Adverse Drug Event
| Article | Year |
|---|---|
The Adjuvant Treatment of Stage III Colon Cancer: Might Less Be More?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Leucovorin; Medication Therapy Management; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Time Factors; Treatment Outcome | 2018 |
5-Fluorouracil and Capecitabine: Assessment and Treatment of Uncommon Early-Onset Severe Toxicities Associated With Administration.
Topics: Acetates; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Patient Safety; Risk Assessment; Severity of Illness Index; Survival Analysis; Uridine | 2018 |
Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Prognosis; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Genetic Markers; Humans; Polymorphism, Genetic; Predictive Value of Tests; Thymidylate Synthase | 2014 |
Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cost-Benefit Analysis; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Genetic Testing; Genotype; Health Care Costs; Humans; Pharmacogenetics; Phenotype; Predictive Value of Tests; Risk Assessment; Risk Factors; Severity of Illness Index | 2016 |
The role of pharmacogenetics in capecitabine efficacy and toxicity.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carboxylesterase; Cytidine Deaminase; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Genome-Wide Association Study; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide; Thymidine Phosphorylase | 2016 |
Biomarker-based selection of therapy for colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; RNA, Messenger; Sequence Analysis, DNA | 2011 |
Safety of capecitabine use in patients with liver dysfunction.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms | 2007 |
19 trial(s) available for capecitabine and Adverse Drug Event
| Article | Year |
|---|---|
Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cystine; Diarrhea; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Glutamates; Hand-Foot Syndrome; Humans; Male; Middle Aged; Stomatitis | 2020 |
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2013 |
Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Prognosis; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Stomach Neoplasms; Treatment Outcome | 2014 |
Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research G
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2014 |
Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Drug Chronotherapy; Drug Monitoring; Drug Screening Assays, Antitumor; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Rectal Neoplasms; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2014 |
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2014 |
Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2015 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; China; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates | 2016 |
Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease-Free Survival; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neovascularization, Pathologic; Ramucirumab; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Receptor, ErbB-2; Taxoids | 2009 |
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chicago; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Survival Analysis | 2011 |
Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Prostatic Neoplasms; Survival Analysis | 2011 |
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Central Nervous System; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2 | 2013 |
Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
Topics: Adult; Age Distribution; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Greece; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Receptor, ErbB-2; Risk Assessment; Risk Factors; Sex Distribution; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2006 |
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; HSP40 Heat-Shock Proteins; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Protein Prenylation; Quinolones | 2006 |
Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Survival Analysis | 2007 |
41 other study(ies) available for capecitabine and Adverse Drug Event
| Article | Year |
|---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Drug-Related Side Effects and Adverse Reactions; Electronic Health Records; Fatigue; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Patient Reported Outcome Measures; Pilot Projects | 2022 |
Assessment of patients' knowledge of their treatment with capecitabine at the National Institute of Oncology in Rabat.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Pharmaceutical Preparations; Prospective Studies | 2023 |
Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database.
Topics: Antimetabolites; Antineoplastic Agents; Capecitabine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Hyperammonemia; Japan; Tegafur | 2023 |
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Genetic Testing; Humans; Pharmacogenomic Variants; Practice Guidelines as Topic | 2020 |
Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiotoxicity; Colorectal Neoplasms; Denmark; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Retrospective Studies; Risk Factors; Young Adult | 2020 |
Combining Adjuvant Radiotherapy With Capecitabine in Chemotherapy-resistant Breast Cancer: Feasibility, Safety, and Toxicity.
Topics: Adult; Breast; Breast Neoplasms; Capecitabine; Case-Control Studies; Chemoradiotherapy, Adjuvant; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Humans; Incidence; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Radiation Injuries; Radiotherapy, Adjuvant; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2020 |
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Drug-Related Side Effects and Adverse Reactions; Female; Ferredoxin-NADP Reductase; Follow-Up Studies; Genotype; Germ-Line Mutation; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Quality of Life | 2020 |
Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboxylic Ester Hydrolases; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Japan; Male; Middle Aged; Oxaliplatin; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Tissue Distribution | 2020 |
Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy.
Topics: Aged; Alleles; Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genetic Variation; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies; Risk Factors; Treatment Outcome | 2021 |
Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genome-Wide Association Study; Genotype; Humans; Male; Middle Aged; Oxaliplatin; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Ribosomal Proteins; Serine-Arginine Splicing Factors; Vomiting | 2021 |
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genotype; Hospitalization; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasms; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Predictive Value of Tests; Prospective Studies; Thymidylate Synthase; Uracil; Young Adult | 2017 |
Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Exome; Female; Genotype; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrimidines | 2017 |
Using pharmacogenetics to prevent severe adverse reactions to capecitabine.
Topics: Capecitabine; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmacogenetics | 2017 |
Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2017 |
Photosensitive lichenoid skin reaction to capecitabine.
Topics: Administration, Topical; Aged; Breast Neoplasms; Capecitabine; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lichenoid Eruptions; Photosensitivity Disorders; Steroids | 2017 |
Come a long way, still a ways to go: from predicting and preventing fluoropyrimidine toxicity to increased efficacy?
Topics: Capecitabine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Pharmacogenetics; Polymorphism, Single Nucleotide | 2018 |
Analysis of data on capecitabine-related adverse drug reactions from the Korean adverse event reporting system database.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Capecitabine; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasms; Republic of Korea | 2018 |
The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gastrointestinal Neoplasms; Genetic Association Studies; Genotyping Techniques; Heterozygote; Homozygote; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Retrospective Studies; Severity of Illness Index; Young Adult | 2019 |
Capecitabine in advanced hepatocellular carcinoma: A multicenter experience.
Topics: Administration, Metronomic; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2019 |
Pyogenic granuloma-like lesions: a novel side effect of capecitabine.
Topics: Capecitabine; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Granuloma, Pyogenic; Humans | 2021 |
MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
Topics: Aged; Biomarkers, Pharmacological; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genetic Association Studies; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic | 2013 |
Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity.
Topics: Adenocarcinoma; Administration, Oral; Aged; Ampulla of Vater; Capecitabine; Chemoradiotherapy; Common Bile Duct Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Incidence; Male; Middle Aged; Pancreatic Neoplasms; Proton Therapy; Radiation Injuries; Radiotherapy Dosage; Retrospective Studies | 2013 |
Paraneoplastic stiff person syndrome associated with colon cancer misdiagnosed as idiopathic Parkinson's disease worsened after capecitabine therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diagnostic Errors; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Middle Aged; Parkinson Disease; Prognosis; Stiff-Person Syndrome | 2013 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies | 2014 |
Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
Topics: Aged; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Costs and Cost Analysis; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Health Care Costs; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2014 |
Effects of gender on capecitabine toxicity in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Retrospective Studies; Sex Characteristics | 2016 |
Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Surface Area; Capecitabine; Drug-Related Side Effects and Adverse Reactions; Female; Hospitalization; Humans; Kidney; Logistic Models; Male; Middle Aged; Odds Ratio; Risk Factors; ROC Curve; Severity of Illness Index; Time Factors; Treatment Outcome | 2016 |
Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation study.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Germany; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2016 |
Outcome Assessments and Cost Avoidance of an Oral Chemotherapy Management Clinic.
Topics: Administration, Oral; Ambulatory Care Facilities; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cost Savings; Costs and Cost Analysis; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Medication Errors; Middle Aged; Outcome Assessment, Health Care; Pancreatic Neoplasms; Patient Care; Patient Compliance; Patient Education as Topic; Rectal Neoplasms | 2016 |
Cardiotoxicity of capecitabine: Captions not to bin.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Early Diagnosis; Humans | 2017 |
Capecitabine cardiotoxicity: How to limit life-threatening events.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Humans | 2017 |
Fatal drug-drug interaction of brivudine and capecitabine.
Topics: Adverse Drug Reaction Reporting Systems; Aged, 80 and over; Antimetabolites, Antineoplastic; Antiviral Agents; Bromodeoxyuridine; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Fatal Outcome; Female; Fluorouracil; Herpes Zoster; Humans; Switzerland | 2009 |
Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Republic of Korea; Retrospective Studies; Risk Factors; Sorafenib; Survival Analysis; Treatment Failure | 2011 |
Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Bevacizumab-based therapy and complication risk after colonic stent placement: is it time for a warning?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colonic Diseases; Colorectal Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Intestinal Obstruction; Intestinal Perforation; Organoplatinum Compounds; Oxaliplatin; Rupture, Spontaneous; Stents | 2010 |
Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Metabolome; Metabolomics; Middle Aged; Neoplasm Metastasis; Nuclear Magnetic Resonance, Biomolecular; Prognosis; Salvage Therapy | 2011 |
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Biomarkers, Tumor; Capecitabine; Carcinoma; Case-Control Studies; Clinical Trials, Phase III as Topic; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Haplotypes; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2011 |
Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Prospective Studies | 2013 |
Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; SEER Program | 2013 |
A new-drug roundup.
Topics: Acetates; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antitubercular Agents; Antiviral Agents; Capecitabine; Cyclopropanes; Deoxycytidine; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Etanercept; Fluorouracil; Humans; Immunoglobulin G; Isoxazoles; Leflunomide; Phosphodiesterase Inhibitors; Piperazines; Purines; Quinolines; Receptors, Tumor Necrosis Factor; Rifampin; Sildenafil Citrate; Sulfides; Sulfones; Thionucleotides | 1999 |